RJ Health Systems’ Senior Vice President of Clinical Analytics, Todd Cooperman (PharmD, MBA, RPh), has written this eye-opening white paper on the current biosimilar market, the challenges of bringing a biosimilar to market, and medical reimbursement for biosimilars.
What does the white paper include?
Gain insight into potential product introductions through 2020 that will impact market competition.
Learn the differences in FDA approval of biologics vs. traditional drugs and how this impacts product launches.
Discover how interchangeability and statutory restrictions apply to biosimilars.